Orelabrutinib-Sintilimab Yields Responses in Primary CNS Lymphoma
The overall response rate at cycle 4 was 61.5%, and none of these patients relapsed.
The overall response rate at cycle 4 was 61.5%, and none of these patients relapsed.
Researchers found that socioeconomic status, insurance, race, and rurality were all associated with telemedicine use.
Most patients completed at-home chemotherapy infusions as planned, and no one stopped treatment because of adverse drug reactions.